-
Events
-
15th International Workshop on Fragile X…
4–7 September, 2011
Continuing a long, successful tradition, the15th International Workshop on…
-
NIH ALS Conference: Clinical Research to…
7–9 September, 2011
This conference is designed to stimulate the development of collaborative…
-
Grover Conference: Risk Factors in…
7–11 September, 2011
At the conclusion of this conference, attendees will be expected to: (1)…
-
Mitochondrial Physiology and Medicine
7–11 September, 2011
An incredibly enriched and ambitious program has been developed including…
-
Delcath Announces Top-Line Results From Metastatic Colorectal Cohort in Phase II Trial of Chemosaturation System
Friday, September 2, 2011
Delcath Systems, Inc. (NASDAQ: DCTH) reported top-line results from the metastatic colorectal (adenocarcinoma) cohort of the Phase II clinical trial of the Delcath chemosaturation system with melphalan in the treatment of patients with unresectable liver cancerThe Company also confirmed plans to i
-
Roche's Tarceva Receives European Approval for First-line Use in a Genetically Distinct Type of Lung Cancer
Friday, September 2, 2011
Personalized approach to cancer medicine allows doctors to identify lung cancer patients who benefit from early treatment with TarcevaRoche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission has approved Tarceva® (erlotinib) for use in patients with a genetically distinct type
-
Repligen Seeks Approval for Imaging Product While Pursuing Rare-Disease Drugs and Manufacturing Platform
Friday, September 2, 2011
Patients who arrive in the emergency room complaining of abdominal pain often have to undergo a type of endoscopy—an invasive and sometimes dangerous test— so doctors can determine if the problem is in the pancreasTaking an MRI scan is a safer alternative, but the resulting images often aren
-
Alexion Gains Mileage Expanding Footprint
Friday, September 2, 2011
Alexion Pharmaceuticals (ALXN) may well have just hit the tip of the iceberg with the number of diseases its drug Soliris can treatSoliris, Alexion's only drug, is approved in over 35 countries to treat one rare life-threatening blood disorder called paroxysmal nocturnal hemoglobinuria, or PNHBut
-
Shire Presents Positive Data From Fabry and Gaucher Disease Studies That Continue to Support Patient Switches to REPLAGAL(R) (Agalsidase Alfa) and VPRIV(R) (Velaglucerase Alfa)
Thursday, September 1, 2011
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced positive data from several studies designed to evaluate the safety of switching to REPLAGAL (agalsidase alfa) from Fabrazyme® (agalsidase beta) and the long-term safety and benefits of switching to VPR
-
Keryx Biopharmaceuticals Announces Completion of Interim Analysis by Data Safety Monitoring Board for the Phase 3 Study of KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer
Thursday, September 1, 2011
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) announced that the independent Data Safety Monitoring Board (DSMB) for the Company's pivotal Phase 3 X-PECT study of KRX-0401 (perifosine) in patients with refractory advanced colorectal cancer has completed a pre-specified interim analysis for safety
-
Texas Children's Hospital Is First Pediatric Hospital in the Nation to Implant Artificial Heart
Thursday, September 1, 2011
Texas Children’s Hospital in Houston announced that it is the first pediatric hospital in the United States to implant an artificial heart into the chest of a 17-year-old patient as the only option to save his lifeThe history-making patient underwent a rare 15-hour operation on May 22 and is cur
-
Jennerex Publishes Clinical Data in Journal, Nature, Demonstrating Intravenous Delivery of Multi-Mechanistic Cancer-Targeted Oncolytic Poxvirus JX-594 to Tumors
Thursday, September 1, 2011
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, announced the publication of clinical data on its lead product JX-594 in the journal NatureFor the first time in humans,
-
Neuraltus ALS Drug Wins Fast Track, Orphan Status
Thursday, September 1, 2011
An experimental treatment for Lou Gehrig’s disease won fast track and orphan drug designations from the Food and Drug Administration, potentially speeding the drug’s development by Neuraltus Pharmaceuticals IncNP-001, the Palo Alto company’s treatment for amyotrophic lateral sclerosis, or AL
-
Minimally Invasive Surgery Now an Option for Children With Scoliosis
Wednesday, August 31, 2011
Minimally invasive surgery to treat scoliosis in teenagers is now a "feasible option," according to Vishal Sarwahi, M.D., Director of Spine Deformity Surgery at Montefiore Medical Center"This new procedure to correct curvature of the spine involves three small incisions in the back, as opposed to